Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kexun Zhou

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Journal of Hematology & Oncology|November 4, 2025
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategiesKexun Zhou, Xinrui Liu, Hong Zhu
Lung Cancer (Amsterdam, Netherlands)|September 3, 2019
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scoresKexun Zhou, Chenlu Jiang, Qiu Li
Frontiers in Oncology|November 29, 2023
Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature reviewKexun Zhou, Yingping Liu, Hong Zhu
BMJ Open|April 23, 2025
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payersCan Jiang, Kexun Zhou, Pei Shu
Frontiers in Immunology|February 27, 2023
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancerKexun Zhou, Shuo Li, Yi Zhao, et al.
International Journal of Nanomedicine|September 2, 2024
Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and TherapyChuanyun Tang, Kexun Zhou, Di Wu, et al.
Frontiers in Pharmacology|June 2, 2023
Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspectiveKexun Zhou, Pei Shu, Hanrui Zheng, et al.
Frontiers in Oncology|December 3, 2019
Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature ReviewMengxi Zhang, Pengfei Zhang, Kexun Zhou, et al.
Medcomm|April 4, 2025
Pancreatic Cancer: Pathogenesis and Clinical StudiesKexun Zhou, Yingping Liu, Chuanyun Tang, et al.
Frontiers in Oncology|November 2, 2023
Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatmentQizhi Ma, Pei Shu, Kexun Zhou, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Journal of Hematology & Oncology|November 4, 2025
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategiesKexun Zhou, Xinrui Liu, Hong Zhu
Lung Cancer (Amsterdam, Netherlands)|September 3, 2019
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scoresKexun Zhou, Chenlu Jiang, Qiu Li
Frontiers in Oncology|November 29, 2023
Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature reviewKexun Zhou, Yingping Liu, Hong Zhu
BMJ Open|April 23, 2025
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payersCan Jiang, Kexun Zhou, Pei Shu
Frontiers in Immunology|February 27, 2023
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancerKexun Zhou, Shuo Li, Yi Zhao, et al.
International Journal of Nanomedicine|September 2, 2024
Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and TherapyChuanyun Tang, Kexun Zhou, Di Wu, et al.
Frontiers in Pharmacology|June 2, 2023
Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspectiveKexun Zhou, Pei Shu, Hanrui Zheng, et al.
Frontiers in Oncology|December 3, 2019
Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature ReviewMengxi Zhang, Pengfei Zhang, Kexun Zhou, et al.
Medcomm|April 4, 2025
Pancreatic Cancer: Pathogenesis and Clinical StudiesKexun Zhou, Yingping Liu, Chuanyun Tang, et al.
Frontiers in Oncology|November 2, 2023
Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatmentQizhi Ma, Pei Shu, Kexun Zhou, et al.
Pageof 4